The NHS has approved a new drug for hundreds of women in England with advanced ovarian cancer that has stopped responding to standard treatment. Mirvetuximab soravtansine, sold under the brand name Elahere and developed by AbbVie, has been fast-tracked through the Cancer Drugs Fund after a positive recommendation from the National Institute for Health and Care Excellence. Up to 400 women a year are expected to qualify. For a patient group that has had no meaningful new pharmaceutical option in over 20 years, the decision carries considerable weight.

The treatment is designated for women with epithelial ovarian, fallopian tube, or peritoneal cancers that have returned and become resistant to platinum-based chemotherapy, which remains the standard first-line approach. Eligibility depends on a further biological condition: the tumour must express a protein called folate receptor alpha, or FRα. Patients whose cancers do not carry this protein are not candidates.

The drug belongs to a class known as antibody-drug conjugates. It works by using a targeting antibody that seeks out and binds to FRα on the surface of cancer cells. Once attached, it releases a cytotoxic agent directly inside the cell. Because the mechanism requires the antibody to locate and latch on to the specific protein, the toxic payload reaches cancer cells without the indiscriminate effect on surrounding tissue that defines conventional chemotherapy. Clinicians have described the approach as something of a precision delivery system, distinguishing it clearly from the broad-spectrum damage caused by earlier treatments.

Clinical trial data from global studies, which included participation from eight hospitals in the United Kingdom, showed that patients receiving the drug survived an average of 16.5 months, against 12.8 months for those on standard chemotherapy. Tumour reduction of at least 30 per cent was observed in 37 per cent of participants, more than double the 16 per cent rate recorded in the comparator group. Side effects reported include fatigue, nausea, low blood counts, and ophthalmic complications including blurred vision and dry eyes. Treating clinicians have noted that these effects are generally more tolerable than those associated with conventional chemotherapy regimens, a distinction that has practical consequences for daily life during treatment.

Patients who moved from chemotherapy to the new drug have described a reduction in the severity of side effects that previously made normal activity difficult. Some reported being able to resume social and family commitments that had become impossible under prior treatment. Ovarian cancer charities have welcomed the NICE recommendation, with several noting that the absence of options after chemotherapy failure had, until now, left families facing a situation with no viable clinical path forward.

Ovarian cancer accounts for roughly 7,500 new diagnoses in the United Kingdom each year and remains the leading cause of death among gynaecological cancers. Approximately 80 per cent of advanced cases eventually relapse. That combination of high relapse rates and limited treatment options after resistance develops has made the condition particularly difficult to manage at later stages. The rollout of mirvetuximab soravtansine begins immediately through specialist hospitals authorised to deliver systemic anti-cancer therapies. Several of those centres had already been involved in the trial phase, meaning the clinical infrastructure for administration was already in place before the formal approval.

Whether the drug extends survival in a manner that proves statistically significant across broader real-world populations remains to be seen as data accumulates outside controlled trial conditions. What is clear is that for the specific subset of patients who are eligible, there is now a treatment pathway where none meaningfully existed before.

‍